Texas
LATEST FROM BIOSPACE
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 13, 2021.
Taysha Gene Therapies has acquired exclusive global rights to TSHA-120, an intrathecally dosed AAV9 gene therapy designed to treat giant axonal neuropathy.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 6, 2021.
A current Phase III trial of the Pfizer-BioNTech COVID-19 vaccine has confirmed the protection remains high for at least six months after the second dose. In a statement, Pfizer and BioNTech reported the vaccine was 91.3% effective against the disease.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Will We Need COVID-19 Vaccines Every Year? Although the jury is still out, a study out of Charité – Universitätsmedizin Berlin suggests that the answer is yes for a few years, but may be unnecessary after a few years post-pandemic.
New markets are emerging, and a new report from the market research team at JLL pinpoints some of these growing areas.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 23, 2021.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 16, 2021.
PRESS RELEASES